Can Supplements Help to Address Acne? With Steven Daveluy, MD

August 14, 2026

Whey protein might be sabotaging your patients' acne treatment, and they have no idea. 🥛 Steven Daveluy, MD breaks down the surprising dairy-acne connection and why probiotics only work when the strain actually matches the condition.
Read more

Why Povorcitinib's JAK1 Mechanism Matters for HS Treatment

August 9, 2026

In a new HCPLive interview, Dr. Martina Porter explains why HS has lagged behind conditions like psoriasis in effective treatment options, and what povorcitinib's arrival could change. As a selective JAK1 inhibitor, it avoids the JAK2/JAK3 pathways linked to hematopoietic side effects, and its oral, needle-free format may appeal to patients hesitant about injections. Because JAK1 inhibition works through a broader pathway than TNF-alpha or IL-17 inhibition, Porter suggests it could offer an alternative for patients who haven't responded to existing biologics, particularly those with early nodular or severe tunneling disease.
Read more

Topical Ruxolitinib Shows Promise for Early-Stage Hidradenitis Suppurativa

July 27, 2026

New Phase 2 data suggest that topical ruxolitinib cream may help address a major unmet need in mild-to-moderate hidradenitis suppurativa. Patients treated with the JAK1/2 inhibitor experienced significant reductions in inflammatory lesions, high clinical response rates, and a favorable safety profile, highlighting its potential as a targeted therapy for early-stage disease.
Read more

The First Doctor an HS Patient Sees Is Usually Not a Dermatologist

July 22, 2026

Most people with hidradenitis suppurativa don't meet a dermatologist first. They meet primary care, OB/GYN, urgent care, or the ER, and that's usually where the 7 to 10 year delay to diagnosis begins. Dr. Steven Daveluy, who has spent over a decade teaching non-dermatology clinicians about HS, breaks down the single question that can catch the disease early, what frontline providers can do while patients wait to see a specialist, and why the upcoming AAD/HSF guidelines could change the financial and clinical case for treatments like laser hair removal.
Read more

Avalo Advances Long-Acting IL-1β Antibody Program for Hidradenitis Suppurativa

July 20, 2026

Avalo Therapeutics has announced the development of AVTX-010, a next-generation anti-IL-1β antibody designed to provide longer dosing intervals for patients with hidradenitis suppurativa. Building on promising Phase 2 results for abdakibart, the program aims to improve treatment convenience, adherence, and patient experience while expanding future therapeutic options in HS.
Read more

Criteria for Hidradenitis Suppurativa Competence Centers

July 12, 2026

An international Delphi consensus involving clinicians and patient representatives from 16 countries has established 23 core criteria for Hidradenitis Suppurativa Competence Centers. The recommendations provide a framework for delivering consistent, multidisciplinary, patient-centered HS care and may help improve access to specialized treatment worldwide.
Read more

Ambulatory Surgery May Be an Option for Troublesome Hidradenitis Suppurativa

July 10, 2026

Surgery isn't just a last resort anymore. A leading dermatologist explains why ambulatory surgery can offer faster relief for troublesome HS lesions, even for patients currently trying today's targeted biologic therapies. Learn when surgical intervention might be worth considering sooner rather than later.
Read more

Beyond the Surface: July 2026

July 8, 2026

Catch the latest from the Hidradenitis Suppurativa Foundation—SHSA 2026 in Tucson, new HS clinical guideline insights, updated resources, and upcoming deadlines you won't want to miss.
Read more

HS in Skin of Color: Bridging Gaps in Diagnosis, Treatment, and Equity

June 22, 2026

In this episode of Skin of Color Savvy, Tiffany Mayo, MD, Steven Daveluy, MD, and patient advocate Jasmine Ivanna Espy unpack the unique challenges of hidradenitis suppurativa (HS) in patients with skin of color, from delayed diagnosis to treatment hesitancy and access barriers. Blending clinical expertise with lived experience, the discussion highlights practical strategies to improve recognition, expand therapeutic confidence, and center patient voices in more equitable HS care.
Read more

The Emerging Role of Povorcitinib in Moderate to Severe Hidradenitis Suppurativa

June 16, 2026

A potential new chapter in hidradenitis suppurativa (HS) treatment is unfolding with povorcitinib, an oral JAK1-selective inhibitor showing promising phase 3 results. In patients with moderate to severe disease—many with prior biologic exposure—clinical response rates improved over time, alongside meaningful reductions in pain and draining tunnels. With generally favorable tolerability and the convenience of once-daily dosing, povorcitinib could help address persistent gaps in HS care and expand options beyond injectable biologics.
Read more

Expanding the HS Treatment Landscape: From Single-Pathway Therapy to Personalized Care

June 15, 2026

The hidradenitis suppurativa (HS) treatment landscape is evolving rapidly, with dozens of biologics and small-molecule therapies in development targeting multiple inflammatory pathways. In this interview, Leandra A. Barnes, MD, FAAD, discusses the shift toward more personalized, patient-centered care, the challenges of treatment dissatisfaction and access barriers, and the promise of emerging therapies that may help improve outcomes for people living with HS.
Read more

Q&A: How Does the Current HS Landscape Look? With Kiera Booth, MD

June 8, 2026

With new biologics expanding treatment options and additional therapies on the horizon, the hidradenitis suppurativa (HS) landscape is rapidly evolving. In this HCPLive Q&A, Kiera Booth, MD, discusses the importance of early diagnosis, individualized treatment selection, procedural approaches such as deroofing, and emerging therapies that may help improve outcomes for patients with HS.
Read more

Pediatric HS Insights: Colleen Cotton, MD, on Early Recognition, Referral, and Comprehensive Care

June 1, 2026

In this video series from Contemporary Pediatrics, Colleen Cotton, MD, FAAD, shares practical guidance on recognizing hidradenitis suppurativa (HS) in children and adolescents, identifying patients earlier through simple screening approaches, understanding key clinical signs, knowing when to refer, and supporting patients beyond medical treatment. These expert perspectives highlight opportunities to reduce diagnostic delays and improve outcomes for pediatric patients living with HS.
Read more

Advanced Antibiotic Strategies in Hidradenitis Suppurativa

May 22, 2026

In this Medscape podcast, expert clinicians discuss the real‑world challenges of caring for patients with hidradenitis suppurativa—covering timely diagnosis, evolving treatment strategies, and the importance of addressing quality‑of‑life burdens. The conversation offers practical insights to help clinicians improve outcomes and support patients over the long term.
Read more

Bimekizumab Shows Durable Responses in Psoriasis and HS Through 3 Years

May 18, 2026

New long‑term data presented at the 2026 AAD Annual Meeting suggest bimekizumab delivers durable disease control in hidradenitis suppurativa, with a growing proportion of patients remaining flare‑free through 3 years and no new safety signals observed. In this brief interview, Steven Daveluy, MD, discusses why extended assessment periods matter in HS, how sustained response influences treatment confidence, and what these findings may mean for long‑term patient care.
Read more

HS Care Has Outgrown Its Standards. The Field Is Catching Up.

May 18, 2026

HS care is evolving—and fast. This article with HS Foundation CEO, Brent Hazelett, explores how traditional standards are struggling to keep up with the realities of hidradenitis suppurativa, and why new, more patient-centered approaches are finally gaining traction. Discover what’s changing, what still needs improvement, and how the field is beginning to close the gap between outdated guidelines and real-world care.
Read more

Advancing Hidradenitis Suppurativa Care: Expert Perspectives on Diagnosis, Treatment, and Patient Impact

May 16, 2026

In this Dermatology Times video series, board-certified dermatologists Dr. Jennifer Hsiao and Dr. Barry Resnik take a comprehensive look at Hidradenitis Suppurativa—from the multidimensional burden and diagnostic challenges to evolving therapies like JAK inhibitors. Through expert insights and practical guidance, this series equips dermatologists to recognize HS earlier, address misconceptions, build patient trust, and improve long-term outcomes.
Read more

Hidradenitis Suppurativa Explained: From Pain and Stigma to Promising New Treatments

May 13, 2026

What exactly is Hidradenitis Suppurativa (HS), and why is it so often misunderstood? On this episode of Science of Skin, dermatologist Dr. Ted Lain and HS expert Dr. Steve Daveluy unpack the biology, burden, and breakthrough therapies shaping the future of HS care.
Read more

New Hope for Adolescents with Hidradenitis Suppurativa

May 11, 2026

A new chapter in care for teens with hidradenitis suppurativa is emerging. With the FDA approval of an additional biologic option, dermatologists now have greater flexibility to intervene earlier, tailor treatment, and potentially prevent lifelong scarring and disease progression. Experts explain why timing matters, how treatment strategies are evolving, and what this milestone could mean for young patients and their families—read on to explore the promise behind this breakthrough.
Read more

Avalo Therapeutics Reports Positive Phase 2 Results for Abdakibart in Hidradenitis Suppurativa

May 7, 2026

Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS clinical trial evaluating abdakibart (AVTX‑009) in adults with moderate to severe hidradenitis suppurativa, supporting continued development toward a Phase 3 program.
Read more

Managing the Psychological Toll of HS

April 24, 2026

Living with hidradenitis suppurativa can take a serious emotional toll—from anxiety and depression to challenges with self-esteem, relationships, and daily life. This article explores why mental health support is a critical part of HS care and offers insight into recognizing, addressing, and treating the psychological burden of the disease. Click to read why caring for your mind matters as much as caring for your skin.
Read more

Understanding Hidradenitis Suppurativa: What You Need to Know

April 24, 2026

Painful lumps, flare-ups in skin folds, delayed diagnosis—hidradenitis suppurativa can be confusing, frustrating, and life-altering. This patient-friendly FAQ explains what HS is (and what it isn’t), who is at risk, why it’s so often misdiagnosed, and what treatment options are available. Click to learn the essential facts every person living with HS should know.
Read more

From Reactive to Proactive: Building Longitudinal Care Plans That Actually Work for Hidradenitis Suppurativa

April 17, 2026

What if dermatologic care didn’t stop at the flare? Discover why shifting from reactive treatment to proactive, longitudinal care plans can lead to better outcomes, stronger patient relationships, and management strategies that truly stand the test of time.
Read more

Beyond the Surface: April 2026

April 10, 2026

Catch the latest from the Hidradenitis Suppurativa Foundation—Board leadership updates, new HS research insights, upcoming clinical guidelines, featured resources, and key events on the horizon.
Read more

Expert Insights on HS: What Every Patient Should Know About Today’s Treatment Landscape

April 1, 2026

In a new episode of the Derms on Drugs podcast, leading dermatology experts discuss the evolving understanding of hidradenitis suppurativa, including treatment strategies, emerging therapies, and what real progress looks like for patients. Tune in to hear practical insights that shed light on where HS care is headed and how it continues to change lives.
Read more

A New Era of Hope for HS: Personalized Treatments Are Changing the Outlook

March 31, 2026

What if HS care could be tailored to you? At the 2026 AAD Annual Meeting, dermatology experts shared how personalized combinations of medical and in‑office surgical treatments are improving outcomes and bringing new hope to people living with moderate to severe hidradenitis suppurativa. Learn how these advances could shape the future of HS care and why they matter now.
Read more

Raising the Bar for HS Outcomes With Barry Resnik, MD

March 15, 2026

Years-long diagnostic delays and incremental treatment approaches have left many patients struggling. Barry Resnik shares how earlier escalation, clearer treatment goals, and a focus on function, not just lesions, could change the trajectory of hidradenitis suppurativa care.
Read more

Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa

March 5, 2026

A team of dermatology experts has just agreed on a standardized way to identify and classify HS lesions, potentially transforming how clinical trials measure disease and evaluate treatments. Find out how this new consensus could reshape research and bring us closer to better therapies.
Read more

Understanding Moderate Hidradenitis Suppurativa: Diagnosis, Impact, and Treatment

February 25, 2026

Explore why early recognition and tailored care are vital for patients with moderate hidradenitis suppurativa. This Dermatology Times piece breaks down key challenges in diagnosis, the real impact on quality of life, and evolving treatment strategies, including when to consider systemic and biologic therapies to prevent disease progression.
Read more

“I Lost 15 Years of My Life”: A Man’s Journey With Hidradenitis Suppurativa

February 25, 2026

In a revealing interview conducted by The Educated Patient, Keven Brown opens up about his long, painful battle with hidradenitis suppurativa — from years of misdiagnosis and physical hardship to the emotional toll of living with a chronic condition and the resilience it took to reclaim his life.
Read more

Do GLP-1 medications help signs and symptoms of Hidradenitis Suppurativa?

February 23, 2026

Could a medication commonly used for type 2 diabetes and weight loss also help improve hidradenitis suppurativa? New research explores the potential impact of GLP-1 receptor agonists on HS signs, symptoms, and quality of life. Click to learn what researchers found and what it could mean for people living with HS.
Read more

Vilobelimab May Improve Clinical Outcomes of HS Patients by Reducing Skin Tunnels

Summary Verified By: Christopher Sayed, M.D. | UNC School of Medicine

February 2, 2026

This study explored the use of vilobelimab, a monoclonal antibody that blocks complement C5a, in treating hidradenitis suppurativa (HS), a chronic skin condition causing painful nodules and abscesses. Although it didn't significantly outperform placebo on overall improvement, high-dose vilobelimab notably reduced skin tunnels. These results suggest further investigation into vilobelimab's potential for managing HS is warranted.
Read more

Hidradenitis Suppurativa in Patients with Skin of Color: Emerging Therapies and Strategies for Effective Management

January 22, 2026

New insights highlight emerging therapies and practical strategies for managing hidradenitis suppurativa in patients with skin of color. Learn how evolving treatments, improved diagnostic approaches, and patient-centered care are reshaping HS management and addressing long-standing gaps in care.
Read more

Timing, Severity, and Therapeutic Choice in Moderate to Severe HS

January 14, 2026

When should HS treatment escalate? This case-based discussion with HS Foundation board member, Dr. Afsaneh Alavi, explores how timing, severity assessment, and therapeutic choice shape outcomes in moderate to severe hidradenitis suppurativa.
Read more

Beyond the Surface: January 2026

January 13, 2026

Catch the latest from the Hidradenitis Suppurativa Foundation — explore new HS insights, updated wound care resources, SHSA 2026 details, and apply for the Mentored Experience Grant by January 31.
Read more

New HS Health Resources Available on Educated Patient

January 5, 2026

A new Hidradenitis Suppurativa Health Resources Hub is now available on the Educated Patient website, offering clear, evidence-based information on HS risk factors, signs and symptoms, diagnosis, treatment options, and more.
Read more

Turning Action Plans Into Power: Personalizing Care for Patients With Hidradenitis Suppurativa

December 16, 2025

Learn how personalized action plans can empower patients with hidradenitis suppurativa by improving communication, clarifying flare management, and supporting more proactive, individualized care.
Read more

Hot Off the Press: SHSA 2025 Abstracts Published in Dermatology & Therapy

December 1, 2025

The full collection of abstracts presented at the 10th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) has officially been published in the open access journal Dermatology & Therapy. This milestone release makes the latest HS research from international clinicians and scientists widely available to the community.
Read more

Making Surgery Results Clearer for HS

Summary Verified By: Christopher Sayed, M.D. | UNC School of Medicine

December 1, 2025

In 2025, experts established a standardized set of definitions for surgical outcomes following procedures for hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. The Delphi consensus method was used to reach agreement on terms like "persistence" and "progression" to better categorize and track patient outcomes. This is a pivotal step towards unifying how surgical results are reported, allowing for better comparison across studies and potentially improving patient care for those with HS.
Read more

How Plastics in Food May Make HS Worse

Summary Verified By: Luis Garza, M.D. Ph.D. | Johns Hopkins

November 28, 2025

A recent study, published in 2025, reveals how chemicals found in plastics, known as endocrine disruptors (p-EDs), may contribute to the skin disease hidradenitis suppurativa (HS) by reducing a protein called Nicastrin, crucial for skin health. Endocrine disruptors are substances that can interfere with hormone systems, potentially causing inflammation akin to the genetic form of HS. This highlights the potential importance of environmental factors in managing and understanding the disease.
Read more

Why HS Is So Often Misdiagnosed, With Steven Daveluy, M.D.

November 25, 2025

Many people with Hidradenitis Suppurativa (HS) suffer in silence — not because the disease is rare, but because it’s too often misunderstood. In a revealing interview, Dr. Steven Daveluy uncovers the myths, missed signals and clinical blind spots that delay diagnosis and care.
Read more

Danby Research Grant Supports New Insights into HS

November 18, 2025

Support from the HS Foundation’s Danby Research Grant enabled Dr. Fang’s work examining the cellular mechanisms involved in HS. Her findings are helping to clarify how immune structures form in the skin and may inform future targeted treatment approaches.
Read more

Optimizing HS Visits: A Dermatologist’s Guide to Compassionate, Effective Care

November 16, 2025

Pain, stigma, and delays still too often define the journey for patients with Hidradenitis Suppurativa (HS). This feature HSF leader, Dr. Gretchen Roth, in the Dermatologist offers dermatologists a roadmap to turn HS visits into moments of trust-building, actionable care, and real hope. From empathetic communication to tailored management strategies, learn how one clinic’s compassion driven approach can reshape outcomes for this complex condition.
Read more

Surgical Collaboration Strengthens HS Outcomes Across Disease Stages

November 4, 2025

Surgery is not just a last resort for Hidradenitis Suppurativa (HS) anymore. New collaborative models between dermatologists, surgeons and researchers are transforming outcomes across all disease stages, from localized cases to advanced disease. Discover how this multidisciplinary shift is redefining HS treatment.
Read more

Alexa Kimball, MD, on the Future of HS Care

October 22, 2025

Dr. Alexa Kimball shares insights on the future of hidradenitis suppurativa care — from earlier diagnosis and better treatment strategies to integrating comorbidities into research. She also explores emerging therapies like GLP-1 receptor agonists and what’s next for advancing HS management.
Read more

Recognizing HS: From First Signs to an Accurate Diagnosis

October 16, 2025

Hidradenitis suppurativa is often misunderstood and underdiagnosed—even though its telltale signs can emerge early. Explore how key symptoms like painful nodules, abscesses, and draining tunnels can offer a pathway to timely diagnosis and more compassionate, effective care.
Read more

Beyond the Surface: October 2025

October 10, 2025

This month’s newsletter features exciting updates on the new HS Buddy Program, details for SHSA 2025 in Nashville, current grant opportunities, and the latest HS in the News. Don’t miss what’s happening in the HS community — check it out now!
Read more

Can Quitting Smoking Lower the Risk of Hidradenitis Suppurativa?

September 29, 2025

A new study of more than 6 million people shows that quitting smoking can cut the risk of hidradenitis suppurativa by about one-third—but the benefits appear only after staying smoke-free for at least three years. Relapsing, however, brings the risk right back up.
Read more

The P2X7-NLRP3 inflammasome inhibitor AZD9056 on HS: Results of a phase 2 trial

Summary Verified By: Kavita Sarin, M.D. Ph.D. | Stanford University

September 27, 2025

In a 2025 study examining the autoimmune skin condition hidradenitis suppurativa (HS), researchers tested the effectiveness of AZD9056, a drug targeting the P2X7 receptor—a protein that plays a role in inflammatory processes. In this small study, AZD9056 did not significantly affect disease severity, indicating the potential for alternate pathways or treatments to target HS more effectively. However, it may restore immune response to certain triggers.
Read more

HS Summit Spotlights Gaps in Diagnosis and Care

September 11, 2025

The summit highlighted the challenges of diagnosing HS, emphasizing the need for awareness & recognizing chronic, recurrent patterns. Patient storytelling & joint panels underscored the real-world burden of HS & the importance of early intervention. Collaboration between patients & providers is crucial for improving outcomes & raising the standard of care in HS management.
Read more